Publications by authors named "Min-Jiang Chen"

Background: Cancer cachexia significantly contributes to morbidity and mortality in patients with non-small-cell lung cancer (NSCLC). Inflammatory pathways mediated by interleukin-6 (IL-6) play a crucial role in the development of cancer cachexia. This study aimed to investigate the use of tocilizumab in the management of NSCLC with coexisting IL-6-elevated cachexia.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the effectiveness and safety of anlotinib versus topotecan for second-line treatment in patients with relapsed small cell lung cancer (SCLC), highlighting the need for better therapeutic options.
  • - Data from 46 patients showed that those treated with anlotinib had a significantly longer progression-free survival (PFS) of 5.6 months compared to 2.2 months for topotecan, but no meaningful difference in overall survival (OS).
  • - Anlotinib also had a higher disease control rate (70%) than topotecan (23%), with treatment-related adverse events being similar between both groups, suggesting anlotinib may be a promising alternative.
View Article and Find Full Text PDF
Article Synopsis
  • - Neuroendocrine neoplasms (NENs) are diverse tumors that originate from neuroendocrine cells, with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) being the most common type.
  • - Recent studies show that GEP-NENs are becoming more prevalent and may have a more aggressive nature than previously thought, leading to limited life expectancy for patients.
  • - The review highlights the need for improved research on diagnosis and management of GEP-NENs, addressing current limitations in understanding their epidemiology, clinical features, and treatments.
View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to create a CT-based radiomic model that could predict how well non-small cell lung cancer patients would respond to PD-1/PD-L1 immunotherapy, using data collected from June 2015 to February 2022.
  • Researchers analyzed CT scans from 237 patients, classifying them as responders or non-responders, and developed a scoring model by extracting and weighting radiomic features.
  • The model showed promising results, with high accuracy rates (AUC of 0.85 in the training set and 0.80 in the test set), outperforming standard PD-L1 models and indicating that these scores can effectively help anticipate patient responses to treatment.
View Article and Find Full Text PDF

Skin wounds are characterized by injury to the skin due to trauma, tearing, cuts, or contusions. As such injuries are common to all human groups, they may at times represent a serious socioeconomic burden. Currently, increasing numbers of studies have focused on the role of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) in skin wound repair.

View Article and Find Full Text PDF

Background: The identification of driver mutations has greatly promoted the precise diagnosis and treatment of non-small cell lung cancer (NSCLC), but there is lack of targeted sequencing panels specifically designed and applied to Chinese NSCLC patients. This study aimed to design and validate of a novel sequencing panel for comprehensive characterization of driver mutations in Chinese NSCLC patients, facilitating further exploration of downstream pathway alterations and therapeutic utility.

Methods: A novel target sequencing panel including 21 driver genes was designed and examined in a cohort of 260 Chinese NSCLC patients who underwent surgery in Peking Union Medical College Hospital (PUMCH).

View Article and Find Full Text PDF

Immunotherapy has dramatically revolutionized the therapeutic landscape for patients with cancer. Although immune checkpoint inhibitors are now accepted as effective anticancer therapies, they introduce a novel class of toxicity, termed immune-related adverse events, which can lead to the temporary or permanent discontinuation of immunotherapy and life-threatening tumor progression. Therefore, the effective prevention and treatment of immune-related adverse events is a clinical imperative to maximize the utility of immunotherapies.

View Article and Find Full Text PDF

Background: Malignant obstructive jaundice (MOJ) is a common pathologic manifestation of malignant biliary obstruction. Recently, several clinical trials have explored the clinical effectiveness of intraluminal I seed-based brachytherapy for MOJ patients, and various outcomes have been reported.

Aim: To assess the efficacy and safety of percutaneous biliary stents with I seeds compared to conventional metal stents in patients with unresectable MOJ.

View Article and Find Full Text PDF

Molecular imaging technology enables us to observe the physiological or pathological processes in living tissue at the molecular level to accurately diagnose diseases at an early stage. Optical imaging can be employed to achieve the dynamic monitoring of tissue and pathological processes and has promising applications in biomedicine. The traditional first near-infrared (NIR-I) window (NIR-I, range from 700 to 900 nm) imaging technique has been available for more than two decades and has been extensively utilized in clinical diagnosis, treatment and scientific research.

View Article and Find Full Text PDF

Background: The pancreatic immune-related adverse event (irAE) is a rare but increasingly occurrence disease with limited knowledge, which was associated with the use of immune checkpoint inhibitors (ICIs).

Methods: In this case series study of pancreatic irAE patients, clinical and radiological manifestations are summarized. Baseline and post-treatment fecal microbiota of immune-related acute pancreatitis (irAP) patients were analyzed by the 16 s rDNA amplicon sequencing method.

View Article and Find Full Text PDF
Article Synopsis
  • A novel MRI contrast agent, A54-CaP, made from calcium phosphate nanoparticles and modified with a liver cancer-targeting peptide, has been developed to improve the diagnosis of primary hepatocellular carcinoma (HCC).
  • These nanoparticles encapsulate Gd-DTPA, a widely used contrast agent, and demonstrate significantly better sensitivity and higher accumulation in liver cells, as indicated by their superior longitudinal relaxivity.
  • In vivo experiments show that A54-CaPNPs provide much better contrast enhancement and imaging duration for HCC detection compared to standard Gd-DTPA, highlighting their potential for non-invasive early diagnosis and timely surgical intervention.
View Article and Find Full Text PDF

An increasing number of patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and develop progressive disease after receiving conventional treatments. In recent years, several novel therapies have been approved for later lines of therapy of previously treated NSCLC. Erlotinib, an EGFR tyrosine kinase inhibitor, was recommended as the second-line therapy for pre-treated patients.

View Article and Find Full Text PDF

Spinal cord injury (SCI) leads to immediate disruption of neuronal membranes and loss of neurons, followed by extensive secondary injury process. Treatment of SCI still remains a tremendous challenge clinically. Minocycline could target comprehensive secondary injury via anti-inflammatory, anti-oxidant and anti-apoptotic mechanisms.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is one of the most common malignancies, giving rise to serious financial burden globally. This study was designed to explore the potential mechanisms implicated with CRC and identify some key biomarkers. CRC-associated gene expression dataset (GSE32323) was downloaded from GEO database.

View Article and Find Full Text PDF

Effective treatment and real-time monitoring of hepatic cancer are essential. A multifunctional calcium phosphate nanoparticles loading chemotherapeutic agent doxorubicin and magnetic resonance imaging contrast agent diethylenetriaminepentaacetic acid gadolinium (A54-CaP/Gd-DTPA/DOX) was developed for visual targeted therapy of hepatic cancer via T1-weighted MRI in real-time. A54-CaP/Gd-DTPA/DOX exhibited a higher longitudinal relaxivity (6.

View Article and Find Full Text PDF

MicroRNA (miRNA or miR) has been shown to play an important role in the initiation and development in many different cancers. Here, we demonstrated down-regulated expression of miR-27a-3p in hepatocellular carcinoma (HCC) tissues in comparison with that in adjacent normal liver tissues based on the TCGA database. Cells viability and apoptosis was measured by CCK-8 and flow cytometry assay.

View Article and Find Full Text PDF

Our study aims to evaluate the efficacy of transcatheter arterial chemoembolization in the treatment of patients with liver metastasis using integrated F-fluorodeoxyglucose positron emission tomography/computed tomography. A total of 97 liver metastasis patients treated by transcatheter arterial chemoembolization were enrolled in this study. The F-fluorodeoxyglucose positron emission tomography/computed tomography images of liver metastasis patients were collected before and after transcatheter arterial chemoembolization treatment.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines how silencing CXCR7 using a lentiviral vector affects tumor invasion and metastasis in hepatocellular carcinoma (HCC) following transcatheter arterial chemoembolization (TACE).
  • Experiments involved cultured HCC cells and a rat model, comparing groups treated with CXCR7-shRNA, TACE, and negative controls to evaluate the effects on cell growth, invasion, and tumor characteristics.
  • Results showed that CXCR7-shRNA reduced the expression of key proteins (CXCR7, MMP-2, VEGF), decreased tumor size, improved survival, and lowered metastasis in treated rats compared to control groups.
View Article and Find Full Text PDF

MicroRNA-126 (miR-126) has been found to promote angiogenesis, but the underlying mechanisms are still unclear. So, we conducted this study to explore the effect of miR-126 expression on angiogenesis in hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). The expression levels of miR-126 and sprouty-related, EVH1 domain containing protein (Spred)1 in surgically resected HCC tissue, HCC tissue with TACE + operation, and tumor-adjacent tissues were determined by quantitative real-time polymerase chain reaction.

View Article and Find Full Text PDF

The current study aimed to develop a method to rapidly, sensitively and practically screen for the epidermal growth factor receptor (EGFR) T790M mutation. This method combines an allele-specific competitive blocker (ACB) with a TaqMan quantitative polymerase chain reaction (PCR) amplification refractory mutation system (ARMS) in a one-step reaction. Using a mimic of a human genomic DNA panel containing serially diluted mutant alleles, the performance efficacy of this method was assessed.

View Article and Find Full Text PDF

Background: Geftinib is widely used in the treatment of advanced non-small cell lung cancer (NSCLC). However, only a small number of reports have described initial failure sites in patients treated with gefitinib. The aim of this study was to investigate survival, recurrence sites, and treatment after recurrence in these patients.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Min-Jiang Chen"

  • - Min-Jiang Chen's recent research primarily focuses on innovative treatment strategies for various forms of cancer, including small cell lung cancer and gastroenteropancreatic neuroendocrine neoplasms, emphasizing the need for improved therapies and a better understanding of disease mechanisms.
  • - His work includes the development of predictive models for tumor response to immunotherapy and exploring the role of gut microbiota in managing immune-related adverse events, indicating a strong interest in both therapeutic efficacy and patient safety.
  • - Additionally, Chen has contributed to the field of precision medicine, with studies involving targeted sequencing panels for non-small cell lung cancer in Chinese patients and novel imaging techniques for tracking tumor responses, reflecting a commitment to advancing personalized cancer care.